Enteric fever, predominantly caused by Salmonella Typhi and Paratyphi, remains a significant health burden, particularly in developing countries. Despite advancements in diagnostic methods and treatment protocols, challenges persist. This article aims to provide an updated approach to its diagnosis and management.
While blood culture remains the gold standard for diagnosis, its sensitivity is variable, ranging from 40% to 80%. Recent advancements include molecular methods such as Polymerase Chain Reaction (PCR) and Loop-Mediated Isothermal Amplification (LAMP), offering improved sensitivity and specificity. Serological tests like Widal test are losing favor due to their low sensitivity and specificity.
Fluoroquinolones, the mainstay of treatment, are now compromised due to increasing resistance. Current guidelines recommend the use of third-generation cephalosporins like ceftriaxone or azithromycin as first-line therapy. The duration of therapy is typically 10-14 days.
Prevention through vaccination is crucial in endemic areas. Two vaccines are currently available: the Vi polysaccharide vaccine and the Ty21a vaccine. Both vaccines are moderately effective and safe but are not recommended for children under two years of age.
Antimicrobial resistance is a significant concern in the management of enteric fever. Continuous surveillance of antimicrobial resistance patterns is essential to guide therapy. The World Health Organization recommends the use of Integrated Surveillance of Antimicrobial Resistance (GLASS) for this purpose.
Enteric fever continues to pose a significant health challenge. Advances in diagnostic methods and treatment protocols, along with vaccination and surveillance of antimicrobial resistance, are crucial in managing this disease. Healthcare professionals should stay updated on these advancements to ensure optimal patient care.
1.
For MDS-Related Anemia, Telomerase Inhibitor Approved.
2.
Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma
3.
Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.
4.
Treating Depression: Crucial for Recovery From Fibromyalgia
5.
In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.
1.
Empowering Oncology with Data: Cloud Security, Real-World Evidence, and Clinical Insights
2.
Immune Regulation of Blood Cell Development
3.
Exploring the Effects of Radiation Therapy on Cystitis: A Journey to Better Health
4.
Transformative Frameworks in Oncology for Better Care
5.
Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment
1.
International Conference on Oncology, Cancer Prevention and Public Health
2.
International Conference on Cancer Nursing and Rehabilitation Strategies
3.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
4.
International Conference on Innovations in Critical Care for Oncology and Cardiology
5.
International Symposium on Oncology, Cardiology and Critical Care Innovations
1.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
2.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
3.
Understanding the causes of anemia in adults beyond nutritional deficiencies
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
5.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation